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and 143 had PS-HF. Mean age, prevalence of ischaemic heart disease and
arrhythmia were 74+/-10, 52% and 44%. The maximal follow up was 88
months and the median follow up was 65 months. Amongst 1,380 patients with
HF, the 413 with RVSP measurement had a worse prognosis than those who
did not (log Rank=0.0001). Patients in the lowest quartile of RVSP
(<17.5mmHg) had a similar prognosis to the subgroup of HF patients without
TR measurement (16% and 17% at 2 years). Mortality increased as function of
the increase in PH (log Rank=0.005). Quartile of RVSP predicted outcome sim-
ilarly in patients with S-HF and PS-HF. Patients in the highest quartile
of RVSP had a 2 year mortality of 38% if S-HF and 35% if PS-HF. On Cox
proportional hazards multivariate analysis, COPD, Age, logNTproBNP, mean
blood pressure and the highest RVSP quartile were independent predictors of
outcome. 
 
Conclusion:
 
 Patients with heart failure and a TR velocity indicating even
mild pulmonary hypertension have a worse prognosis whether or not LV sys-
tolic function is impaired. Patients with more severe PH have an even worse
outcome. PH is an independent predictor of outcome in HF.
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Both biologically active BNP1-32 and inactive NT-proBNP1-76 are
released in circulation from prohormone, proBNP1-108. Recent data suggest
that proBNP is detected in blood of heart failure (HF) patients. Blood levels,
kinetics as well as determinants of proBNP1-108 secretion are unknown as
compared to processed forms. We sought to measure and to compare blood
levels of BNP and proBNP in HF and non HF patients.
 
Methods:
 
 plasma natriuretic peptides were assessed in 131 HF patients and
in 36 non-HF patients using both Triage BNP assay and BioRad proBNP
assay. BioRad assay is highly specific of proBNP when the Triage BNP assay
may be influenced by proBNP. Among HF patients, 33 were admitted because
of acute HF and blood samples were analyzed on admission and at discharge.
In order to compare BNP and proBNP levels, results are expressed as nmole/l.
 
Results:
 
 ProBNP was detected in all patients (104 ± 145 nmol/l) and dem-
onstrated a high degree of correlation with BNP in non-HF patients (r = 0.95
[95% IC 0.90 – 0.97], p<0.0001) as well as in HF patients (r = 0.97, [0.95 -
 0.98], p<0.0001). The proBNP/BNP ratio was higher in HF patients as com-
pared to non-HF patients (0.82 ± 0.23 versus 0.62 ± 0.18, p < 0.0001). In
patients with decompensated HF, proBNP/BNP ratio were similar on admis-
sion and at discharge, and changes in both BNP and proBNP were similar
(0.91, [0.82-0.95], p < 0.0001). Interestingly, proBNP/BNP ratio was lower in
the most severe HF patients according to discharge BNP and proBNP/BNP
ratio was negatively correlated with discharge BNP (r = -0.40, [-0.65 – -0.06],
p 0.02).
 
Conclusion:
 
 the intact precursor – proBNP- to both BNP and NT-proBNP
circulates in both HF and non-HF patients and is an important part of the pool
of circulating natriuretic peptides. HF seems to be characterized by a decrease
in proBNP processing but, unexpectedely, at a lesser level in acute and/or
severe HF as compared with less severe HF. Biological and physiological
meanings of our results deserves further studies.
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Ten-year in-hospital mortality trend for patients hospitalized for
heart failure in a single French heart failure clinic
 
Patrick Jourdain (1), Zuily Stéphane (2), Daniel Decup (3), Nelly Agrinier
(4), Serge Groshens (3), Yves Juillière (2), Francois Alla Alla (4)
 
(1) CH R Dubos, UT d’insuffisance cardiaque, Pontoise, France – (2)
Nancy University Hospital, Department of Cardiology, Vandoeuvre-Lès-
Nancy, France – (3) CH René Dubos, Department of medicoeconomic
analysis, Pontoise, France – (4) Nancy University, School of Public
Health, Vandoeuvre-Lès-Nancy, France
 
Background: 
 
Heart Failure (HF) is a frequent and severe disease. Overall
prognosis of systolic HF is poor, and one-year survival rate is lower than most
cancers. For that reason, HF units were progressively created in cardiology
departments according to the European guidelines.
 
Aim: 
 
The aim of this study was to describe the evolution in all-cause in-
hospital mortality in patients hospitalized for HF in the HF clinic created at
René Dubos hospital (Pontoise, France).
 
Methods:
 
 We conducted a descriptive study of all-cause in-hospital mor-
tality in a whole population of 4801 patients hospitalized for HF (range per
year: 248-640 patients) from January 1997 to December 2007 in our HF clinic.
Chi square, test for trend and linear regression were performed.
 
Results:
 
 Our population consisted of 2331 men (48.6%) with a mean age
per year ranging from 67.8 to 75.8 years, and a percentage of patients pre-
senting with systolic HF (LVEF<45%) of 53.8%. There were no significant
differences in terms of sex, diabetes mellitus or LVEF<45%, except for age
and renal insufficiency. All-cause in-hospital mortality rate for patients hospi-
talized for HF appeared to be significantly decreasing during ten-year follow-
up (p<0.0001) (see figure). Moreover we noticed that average length of hos-
pital stay was decreasing during ten-year follow-up (p=0.027, -0.3 day per
year).
 
Conclusion:
 
 Mortality in HF patients was confirmed to be decreasing
during the last ten-year period, thereby confirming the impact of HF care man-
agement on HF prognosis. 
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While the major role played by hypertension (HT) in the genesis of chronic
heart failure (HF) is well known, the main risk factors leading to HF in hyper-
tensive patients remain poorly investigated. O-PREDICT 2 was a multicentre,
observational study conducted with 1537 general practitioners who recruited
4427 consecutive hypertensive outpatients (pts) (mean age 72±9 years; 66%
males). We compared pts with a clinical history of HF (group 1, n=2969) and
without HF (group 2, n=1458, age > 65 yrs).
 
Results:
 
 Sex ratio and age were similar between groups. Duration of HT
was higher (P<.05) in group 1 (14± 8 
 
vs.
 
 11± 8 years in group 2). Blood pres-
sure was lower in group 1, with 49.4% pts having SBP 
 
≥
 
 140 mmHg vs.
60.9% in group 2. The number of cardiovascular risk factors ranged from 0 to
11 with a median of 4 in group 1, and from 0 to 10 with a median of 2 in
group 2; 74.3% of pts in group 1 vs. 45.6% in group 2 had more than 3 risks
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factors (P<.05). Using multivariate analysis, left ventricular hypertrophy
(LVH) was the strongest risk factor of HF (OR= 25.4, 95%CI=21-31), fol-
lowed by the presence of heart valve disease (OR=4.1, 95%CI=2.7-6.3), par-
oxystic or permanent atrial fibrillation (OR=4.05, 95%CI=3.1-5.3), renal
dysfunction, history of myocardial infarction and coronary artery disease
(OR<3 for each of them).
 
Conclusion:
 
 As suspected, LVH is the strongest risk factor for HF in
hypertension, while a majority of pts presented with > 3 risk factors for HF.
This study highlights the need for an early management of HF risk factors in
hypertensive pts. 
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We evaluated left ventricular remodeling (LVR) in patients (pts) with
heart failure (HF) of the 2 main aetiologies, coronary artery disease (CAD)
and dilated cardiomyopathy (DCM) after 1 year (y) of cardiac resynchroniza-
tion therapy (CRT). We enrolled 65 HF outpts with CRT indication (mean
age 67.5±13.2 ys 74.6% males, M): 33 had CAD-caused HF (70.2±6.7 ys,
84.4% M) and 32 DCM (64.6±17.3 ys, 64.5% M). All underwent ECG,
echocardiography, NYHA evaluation before and after 1 y of CRT. Before
CRT, NYHA was similar (CAD 2.7±0.7, DCM 2.7±0.8) and after 1 y it sig-
nificantly (p<0.05) and equally improved in both (CAD 2.3±0.5, DCM
2.2±0.7). Before CRT left ventricular ejection function (EF,%) was signifi-
cantly (p=0.04) less in DCM (22.9±7.7) than CAD (26.3±7.3) while end-dias-
tolic (EDV, ml) and end-systolic (ESV) volume, end-diastolic (EDD, mm)
and end-systolic (ESD) diameter were significantly greater in DCM than
CAD (EDV 239±78 vs 207±62 p=0.04, ESV 192±81 vs 152±57 p=0.03,
EDD 72.8±8.1 vs 68.8±8.6 p=0.05, ESD 59.5±10.7 vs 53.8±8.8 p=0.03).
After 1 y EF significantly improved in both (DCM 28.8±9.5 p=0.01, CAD
29.5±7.4 p=0.05) with a borderline trend to a greater increase in DCM. After
1 y EDV, ESV, EDD and ESD were reduced in both, with a significant reduc-
tion only in DCM. Expressing LVR as the volume parameters variation (
 
Δ
 
),
it was significantly greater in DCM than CAD: 
 
Δ
 
EDV DCM 44±72 vs CAD
20±34, p=0.04; 
 
Δ
 
ESV DCM 47±64 vs CAD 19±35, p=0.04. Before CRT
QRS duration (msec) was similar in both (DCM 172±33 CAD 176±28, p=ns)
as well as after (DCM 123±33 CAD 134±31, p=ns). Pre and post-CRT QRS
duration and 
 
Δ
 
QRS weren’t related to any modification of the above indi-
cated parameters, both in the overall population and the 2 groups. Thus, CRT
determines EF increase and LVR regression in both examined HF aetiologies.
Volume reduction is greater in DCM than CAD. No relation exists between
the volume and function parameters modifications and QRS duration both
before and after CRT. 
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Purpose:
 
 It remains unknown whether heart rate reduction by the I
 
f
 
 current
inhibitor ivabradine (IVA) improves left ventricular (LV) function of the inf-
arcted and reperfused myocardium. Accordingly, our goal was to investigate
the effect of IVA on global and regional LV function following myocardial
infarction and long term reperfusion in rabbits.
 
Methods:
 
 Myocardial systolic function was assessed before a 20 min cor-
onary artery occlusion and during the subsequent 3 weeks of reperfusion by
echocardiography and tissue tracking imaging. Throughout reperfusion, rabbits
received either IVA (10 mg/kg/day, n=9) or vehicle (Control, n=8) using
implanted osmotic pumps. At 3 weeks reperfusion, LV remodeling was inves-
tigated by histology and expression of several proteins (SERCA2a, RyR2-P,
phospholamban, FKBP12) involved in calcium handling.
 
Results:
 
 After 3 weeks, IVA induced a significant decrease in heart rate by
 
≈
 
20% as compared to Control (214±9 
 
vs
 
 266±14 bpm, respectively). In Con-
trol rabbits, ejection fraction and regional systolic displacement were signifi-
cantly decreased as compared to baseline values (43±4% vs 63±2% and
1.4±0.2 vs 2.8±0.2 mm, respectively) and were associated with LV enlarge-
ment and interstitial fibrosis within the reperfused zone (risk zone: 30±2% of
LV and infarct size: 8% of LV). Chronic administration of IVA prevented the
reduction in ejection fraction (58±3% vs 66±3% in baseline) and the decrease
in regional systolic displacement (1.9±0.3 vs 2.6±0.3 mm). This improvement
was not related to a difference in infarct size and interstitial fibrosis. Interest-
ingly, this was associated with a significant increase in FKBP12 expression in
the reperfused area without any changes in SERCA2a, RyR2-P and phospho-
lamban.
 
Conclusion:
 
 
 
Heart rate reduction with IVA significantly improves systolic
function after 3 weeks of reperfusion. This beneficial effect might result from
an adaptation of calcium handling as suggested by the increase in FKBP12
expression.
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The aim
 
 of the present work was to investigate changes in heart architec-
ture after chemical sympathetic denervation by 6OH-Dopamine (6OH-DA) in
mice.
Two months old mice (n=18) received 3 6OH-DA injections (200 mg/kg,
ip) or saline (n = 6) at 3 days of interval. 15 and 30 days after first injec-
tion, heart rate spectral variability (HRV, FFT) was analyzed in low frequency
(LF: 0.15-1.5 Hz) and high frequency (HF: 1.5-5 Hz) ranges and LH/HF ratio
was calculated. After sacrifice, blood was withdrawn for catecholamine deter-
mination (HPLC). Hearts were fixed (formaldehyde 10%) for histology or
frozen for western blot analysis (tyrosine hydroxylase, TH).
 
Results
 
 indicate that compared to controls (1410±145 pg/ml) plasma nore-
pinephrine levels were significantly lower at D15 (766±186 pg/ml) and D30
(675±288 pg/ml) after 6OH-DA without change in epinephrine. TH expression
was absent at D15 and significantly lower than in controls at D30. When com-
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